PCVX Earnings Date: Nov 3, 2026 (Estimated) — Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PCVX's next earnings date?
Vaxcyte, Inc. (PCVX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.11 on revenue of $12.5M.
How did PCVX do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Vaxcyte, Inc. posted EPS of -$1.97 versus the -$2.06 estimate, a beat of 0.0%. Revenue was $0 against a $12.5M estimate. The stock's 1-day post-earnings move was +5.3%.
How much does PCVX stock move after earnings?
PCVX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.3% (up or down) in the day after earnings.
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -2.06 | -1.97 | +0.00% | $0 | ✅ Beat | +5.31% | +6.67% | +9.39% |
| 2026-05-06 | Q1 2026 | -1.79 | -2.30 | -28.49% | $0 | ❌ Miss | -9.84% | -4.99% | -17.06% |
| 2026-02-24 | Q4 2025 | -1.49 | -1.80 | -20.81% | $0 | ❌ Miss | +2.75% | -2.49% | -8.87% |
| 2025-11-04 | Q3 2025 | -1.25 | -1.56 | -24.80% | $0 | ❌ Miss | -2.49% | +10.42% | +11.41% |
| 2025-08-06 | Q2 2025 | -1.15 | -1.22 | -6.09% | $0 | ❌ Miss | -9.06% | -4.39% | +0.06% |
| 2025-05-07 | Q1 2025 | -0.92 | -1.04 | -13.04% | $0 | ❌ Miss | +8.45% | +1.45% | +27.55% |
| 2025-02-25 | Q4 2024 | -1.14 | -1.02 | +10.53% | $0 | ✅ Beat | -0.88% | -11.48% | -13.60% |
| 2024-11-05 | Q3 2024 | -1.11 | -0.83 | +25.23% | $0 | ✅ Beat | -3.24% | -7.61% | -16.29% |
Showing last 8 quarters.